Early patient data suggests that FlowOx™ may have a role in Multiple Sclerosis (MS) symptoms management

Preliminary results from an exploratory pilot investigation carried out by Neuro-SysMed, Norway’s leading center of excellence in Neurological research, were presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)1.

Based on the promising results from the pilot study at Haukeland, Otivio and NeuroSysmed decided to initiate a larger randomized controlled trial in Scandinavia.

1 www.ectrims.eu


First RCT to show improved walking capacity

First multi-centre randomized controlled trial using FlowOx™, published in Journal of Vascular Surgery, shows improved walking capacity for patients with intermittent claudication, also known as “windows shopper’s disease”.

Read more here!



Is FlowOx™ for me?

What is FlowOx™?

A revolutionary new technology for the treatment of reduced peripheral micro circulation

How does it work?

FlowOx™ works by exercising the blood vessels from the small arteries to the capillaries in the outer layers of the skin.

Who can benefit from using FlowOx™?

FlowOx™ is recommended for patients of over 18 years who suffer from blood flow deficiencies in the lower limbs such as:

a) Peripheral arterial disease (PAD),
b) Diabetic and non-diabetic arteriopathic foot and leg ulcers,
c) Intermittent claudication and rest pain,
d) Foot and lower leg ulcers of mixed aetiology associated with immobility such as paraplegia following spinal injury.

Can FlowOx™ be integrated into an existing therapy?

FlowOx™ is an additional treatment and can be used in conjunction with standard care (typical wound care and medication).

Without FlowOx™ I would have lost my other leg as well and I am not sure I would have been here today. That is what FlowOx™ has done for me..
Stine, Norway

Listen to Stine’s and Hans Thomas’ stories

Stine’s own story

First FlowOx™ patient, Hans Thomas


FlowOx™ by Otivio

Otivio AS is a Norwegian medtech company based in Oslo. FlowOx™ is a non-invasive medical device for home treatment addressing insufficient blood flow to the limbs associated with peripheral arterial disease, diabetes and other arterial blood flow deficiencies. FlowOx™ is documented to reduce or eliminate these outcomes which represent a big impact on Quality of Life and health care costs. FlowOx™ is CE marked (CE2460) and available in various countries.

Read more about Otivio


Contact us to get more information about FlowOx™

Scroll to Top